Abstracts

37 – Post-Tuberculosis Disease: Opening Pandora’s Box

This talk will highlight the burden and spectrum of post-tuberculosis disease, focusing on the complexities of clinical presentation and pitfalls in assessment. We will give an overview of pathogenesis, and an update of recent work in post-tuberculosis lung disease (PTLD). We will highlight important knowledge gaps in the field, and will discuss ongoing work and…

48 – Long-Acting InSTI Strategies: Understanding the Risks for Failure and Resistance

Long-acting injectables (LAI) represents one of the most significant advances in antiretroviral therapy in recent years, offering durable suppression for PLWH who find daily oral medications challenging. Confirmed virological failure (CVF) is a low-incidence (1.4% over 152 weeks) but high-consequence event, with almost all developing drug-resistant mutations. This is in contrast to daily oral INSTI-based…

21 – Advanced HIV Disease in Children

In 2025, late diagnosis of HIV in children continues to be a significant global concern, with many presenting with advanced HIV disease (AHD). This issue contributes to a considerable number of hospital admissions, particularly among infants, due to acute conditions such as pneumonia, sepsis, and diarrhea. These acute illnesses are frequently accompanied by important by…

32 – Landscape of Proviral Integration in HIV-1 Reservoir & Relationship to Latency & Reactivation

HIV-1 persists in a mostly latent state within blood and tissues during suppressive ART. Proviral integration sites may play a critical role in the establishment and maintenance of this latent reservoir. Understanding the landscape of proviral integration is essential for deciphering the mechanisms behind HIV-1 latency and reactivation. Recent studies have shed light on the…

36 – Long-Acting Treatments for Tuberculosis

Long-acting injectable formulations are revolutionizing HIV treatment and prevention and have similar potential to improve the treatment and prevention of tuberculosis, including simpler, shorter regimens and expanded treatment options. This presentation will describe how long-acting injectable formulations could address important obstacles to ending the world’s oldest pandemic, review recent progress in the development of long-acting…

1 – Session Overview for the Scott M. Hammer Workshop for New Investigators and Trainees

Over the past four decades, remarkable progress has been made in understanding HIV epidemiology, pathogenesis, treatment, and prevention from the combined efforts of community members, clinicians, investigators, and funding agencies worldwide. Yet more work and new approaches are needed to achieve the ambitious goal of ending the epidemic and ensuring optimal quality of life for…

14 – Martin Delaney Presentation: 40+ Years of HIV: What’s Changed, What Hasn’t, What Shouldn’t, What Must

We are gathering in a moment of tremendous challenges and opportunities. We have developed biomedical tools to prevent HIV transmission and support the wellbeing of over 38 million individuals living with HIV, yet a truly healthy world eludes us. Stigma, discrimination, preventable deaths, and inequitable access to resources and health care persist. Human rights that…